-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34

Benzinga·09/25/2026 11:58:37
Listen to the news
BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.